One year of first-line therapy for CLL for the prospect of more than 5 years of treatment freedom¹

The BCL2 inhibitor venetoclax has been approved in Switzerland as a first-line therapy for chronic lymphocytic leukemia (CLL) since November 16, 2023 [2]. This is based on the results of the CLL14 study, the 6-year data of which were presented at the European Hematology Association Congress in Frankfurt on June 9, 2023 [1]. The data give CLL patients the prospect of more than 5 years of treatment freedom after less than one year of combined treatment with venetoclax and obinutuzumab [1, 2].